Medicines
Find Medicines
Search 21,000+ medicines by brand, generic, indication, or drug class
Magaplus-X
Magaldrate + Simethicone
Magaplus-X
Magaldrate + Simethicone
Indications
Peptic ulcer disease
Indication detailsView
This is indicated to relieve symptoms of dyspepsia, heartburn, acid indigestion, sour stomach, gastroesophageal reflux and hiatal hernia. It is also prescribed in hyperacidity associated with peptic ulcers, gastritis and esophagitis. Magaldrate may be given to children if necessary. Also indicated for the relief of flatulence, abdominal distension and windy colic.
Therapeutic classView
Antacids, Anti-dyspeptic/Carminatives
PharmacologyView
This is a combination of magaldrate and simethicone. Magaldrate (magnesium aluminium compound i.e. Hydroxymagnesium Aluminate), which neutralizes gastric acid extraordinarily quickly without raising the pH above 5-6. It also decreases the activity of pepsin in gastric secretion. Besides this, simethicone, the another component of Marlox Plus, enables the gas buble to coalesce and give relief from flatulence.
DosageView
Tablet: 1-4 chewable tablets, 20 to 60 minutes after meals and at bedtime, or as directed by the physician.
Suspension: 2-4 teaspoonfuls (10-20 ml) of suspension, 20 to 60 minutes after meals and at bed time, or as directed by the physician.
Suspension: 2-4 teaspoonfuls (10-20 ml) of suspension, 20 to 60 minutes after meals and at bed time, or as directed by the physician.
Side effectsView
Gastrointestinal side-effects are uncommon. Occasionally, if excessive amount is consumed, diarrhea, constipation or regurgitation may occur.
ContraindicationsView
Magaldrate is contraindicated in patients with known hypersensitivity to magnesium and aluminium. It is also contraindicated in patients with impaired renal functions.
PrecautionsView
Care should be taken in decreased kidney function, hypophosphataemia and weak people.
InteractionsView
It should not be used in patients taking any form of Tetracycline. The drug may cause reduced bio-availability or slower absorption of a number of drugs including propranolol, isoniazid, prednisolone and naproxen.
Pregnancy & lactationView
Magaldrate may be used in pregnancy if indicated however one should avoid excessive dosage. Magaldrate may pass into breast milk but has not been reported to cause problem in nursing babies.
Overdose effectsView
Over dosage with this formulation is a rare case.
StorageView
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
Magasol
Magaldrate + Simethicone
Magasol
Magaldrate + Simethicone
Indications
Peptic ulcer disease
Indication detailsView
This is indicated to relieve symptoms of dyspepsia, heartburn, acid indigestion, sour stomach, gastroesophageal reflux and hiatal hernia. It is also prescribed in hyperacidity associated with peptic ulcers, gastritis and esophagitis. Magaldrate may be given to children if necessary. Also indicated for the relief of flatulence, abdominal distension and windy colic.
Therapeutic classView
Antacids, Anti-dyspeptic/Carminatives
PharmacologyView
This is a combination of magaldrate and simethicone. Magaldrate (magnesium aluminium compound i.e. Hydroxymagnesium Aluminate), which neutralizes gastric acid extraordinarily quickly without raising the pH above 5-6. It also decreases the activity of pepsin in gastric secretion. Besides this, simethicone, the another component of Marlox Plus, enables the gas buble to coalesce and give relief from flatulence.
DosageView
Tablet: 1-4 chewable tablets, 20 to 60 minutes after meals and at bedtime, or as directed by the physician.
Suspension: 2-4 teaspoonfuls (10-20 ml) of suspension, 20 to 60 minutes after meals and at bed time, or as directed by the physician.
Suspension: 2-4 teaspoonfuls (10-20 ml) of suspension, 20 to 60 minutes after meals and at bed time, or as directed by the physician.
Side effectsView
Gastrointestinal side-effects are uncommon. Occasionally, if excessive amount is consumed, diarrhea, constipation or regurgitation may occur.
ContraindicationsView
Magaldrate is contraindicated in patients with known hypersensitivity to magnesium and aluminium. It is also contraindicated in patients with impaired renal functions.
PrecautionsView
Care should be taken in decreased kidney function, hypophosphataemia and weak people.
InteractionsView
It should not be used in patients taking any form of Tetracycline. The drug may cause reduced bio-availability or slower absorption of a number of drugs including propranolol, isoniazid, prednisolone and naproxen.
Pregnancy & lactationView
Magaldrate may be used in pregnancy if indicated however one should avoid excessive dosage. Magaldrate may pass into breast milk but has not been reported to cause problem in nursing babies.
Overdose effectsView
Over dosage with this formulation is a rare case.
StorageView
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
Magfin
Magnesium Hydroxide + Liquid Paraffin
Magfin
Magnesium Hydroxide + Liquid Paraffin
Indications
Constipation
Indication detailsView
This preparation is indicated in-
- Constipation
- Hyperacidity with constipation
- Anorectal disorder
- Post-operative constipation
- Constipation associated with chronic cholecystitis
- Hernia
Therapeutic classView
Antacid with laxative action
PharmacologyView
This preparation has a dual-relief formulation containing a gentle laxative ingredient and a lubricant which eases the discomfort associated with straining and bowel movement. It is recommended for the temporary relief of constipation
DosageView
The recommended oral dose are as follows-
Adults: 15-30ml before breakfast or at bedtime.
Children:
Adults: 15-30ml before breakfast or at bedtime.
Children:
- Over 7 years: 7.5 ml-15 ml at bedtime.
- 3-7 years: 5-10 ml at bedtime.
Side effectsView
Rectal irritation, potassium loss (thirst, weakness, nausea and diarrhea).
ContraindicationsView
Acute Gl conditions like abdominal pain.
PrecautionsView
Renal and hepatic impairment. Maintain adequate fluid intake.
InteractionsView
Cimetidine, Diuretics, Famotidine and Ranitidine may cause irritation of stomach or bowel.
Pregnancy & lactationView
Can be given to pregnant and lactating mother.
Overdose effectsView
There are no reported cases of overdosage.
StorageView
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
Magmil
Magnesium Hydroxide
Magmil
Magnesium Hydroxide
Indications
Osmotic laxative
Indication detailsView
Magnesium Hydroxide suspension is used in constipation, heart burn, gas and nausea. It is also indicated in acute and long acting constipation due to hyper acidity and peptic ulcer or stomatitis.
Therapeutic classView
Antacid with laxative action
PharmacologyView
Magnesium Hydroxide is popularly known as Milk of Magnesia. It is a mildly acting antacid and laxative. It is poorly and slowly absorbed and acts by its osmotic properties in the luminal fluid which causes retention of fluid in the bowel. It is useful for emptying the bowel prior to surgical, radiological and colonoscopic procedures and can help to eliminate parasites following appropriate therapy and toxic material in some cases of poisoning. Magnesium Hydroxide is converted into Magnesium Chloride in the stomach without forming carbon dioxide
DosageView
As Laxative:
- Adults: 2-4 Tablespoonful with a full glass of water.
- Children: 6-11 years: 1-2 Tablespoonful with a full glass of water. 2-5 years: 1-3 Teaspoonful with a full glass of water.
- Adults: 1-3 teaspoonful (5 to 15 ml) up to 4 times daily with water.
- Children: 1-3 years: ¼ teaspoonful. 3-6 years: ¼-½ teaspoonful. 6-12 years: ½-1 teaspoonful
Side effectsView
Magnesium Hydroxide in common with other magnesium salts may cause diarrhoea.
ContraindicationsView
Magnesium Hydroxide should not be administered where use of laxative is contraindicated. Long term treatment of Magnesium Hydroxide is contraindicated in patients with renal failure.
PrecautionsView
The drug should be avoided if possible in patients with renal and hepatic failure and in those with heart block and myocardial disease. The drug may be used cautiously in pregnancy.
InteractionsView
Magnesium hydroxide can decrease the absorption of other drugs such as, digoxin, mycophenolate, phosphate supplements (e.g., potassium phosphate), tetracycline antibiotics, certain azole antifungals (ketoconazole, itraconazole), and quinolone antibiotics (e.g., ciprofloxacin, levofloxacin).
StorageView
Store in a cool & dry place, protected from light. Keep all medicines out of reach of children.
Magnamilk
Magnesium Hydroxide
Magnamilk
Magnesium Hydroxide
Indications
Osmotic laxative
Indication detailsView
Magnesium Hydroxide suspension is used in constipation, heart burn, gas and nausea. It is also indicated in acute and long acting constipation due to hyper acidity and peptic ulcer or stomatitis.
Therapeutic classView
Antacid with laxative action
PharmacologyView
Magnesium Hydroxide is popularly known as Milk of Magnesia. It is a mildly acting antacid and laxative. It is poorly and slowly absorbed and acts by its osmotic properties in the luminal fluid which causes retention of fluid in the bowel. It is useful for emptying the bowel prior to surgical, radiological and colonoscopic procedures and can help to eliminate parasites following appropriate therapy and toxic material in some cases of poisoning. Magnesium Hydroxide is converted into Magnesium Chloride in the stomach without forming carbon dioxide
DosageView
As Laxative:
- Adults: 2-4 Tablespoonful with a full glass of water.
- Children: 6-11 years: 1-2 Tablespoonful with a full glass of water. 2-5 years: 1-3 Teaspoonful with a full glass of water.
- Adults: 1-3 teaspoonful (5 to 15 ml) up to 4 times daily with water.
- Children: 1-3 years: ¼ teaspoonful. 3-6 years: ¼-½ teaspoonful. 6-12 years: ½-1 teaspoonful
Side effectsView
Magnesium Hydroxide in common with other magnesium salts may cause diarrhoea.
ContraindicationsView
Magnesium Hydroxide should not be administered where use of laxative is contraindicated. Long term treatment of Magnesium Hydroxide is contraindicated in patients with renal failure.
PrecautionsView
The drug should be avoided if possible in patients with renal and hepatic failure and in those with heart block and myocardial disease. The drug may be used cautiously in pregnancy.
InteractionsView
Magnesium hydroxide can decrease the absorption of other drugs such as, digoxin, mycophenolate, phosphate supplements (e.g., potassium phosphate), tetracycline antibiotics, certain azole antifungals (ketoconazole, itraconazole), and quinolone antibiotics (e.g., ciprofloxacin, levofloxacin).
StorageView
Store in a cool & dry place, protected from light. Keep all medicines out of reach of children.
Magnason
Magnesium Hydroxide
Magnason
Magnesium Hydroxide
Indications
Osmotic laxative
Indication detailsView
Magnesium Hydroxide suspension is used in constipation, heart burn, gas and nausea. It is also indicated in acute and long acting constipation due to hyper acidity and peptic ulcer or stomatitis.
Therapeutic classView
Antacid with laxative action
PharmacologyView
Magnesium Hydroxide is popularly known as Milk of Magnesia. It is a mildly acting antacid and laxative. It is poorly and slowly absorbed and acts by its osmotic properties in the luminal fluid which causes retention of fluid in the bowel. It is useful for emptying the bowel prior to surgical, radiological and colonoscopic procedures and can help to eliminate parasites following appropriate therapy and toxic material in some cases of poisoning. Magnesium Hydroxide is converted into Magnesium Chloride in the stomach without forming carbon dioxide
DosageView
As Laxative:
- Adults: 2-4 Tablespoonful with a full glass of water.
- Children: 6-11 years: 1-2 Tablespoonful with a full glass of water. 2-5 years: 1-3 Teaspoonful with a full glass of water.
- Adults: 1-3 teaspoonful (5 to 15 ml) up to 4 times daily with water.
- Children: 1-3 years: ¼ teaspoonful. 3-6 years: ¼-½ teaspoonful. 6-12 years: ½-1 teaspoonful
Side effectsView
Magnesium Hydroxide in common with other magnesium salts may cause diarrhoea.
ContraindicationsView
Magnesium Hydroxide should not be administered where use of laxative is contraindicated. Long term treatment of Magnesium Hydroxide is contraindicated in patients with renal failure.
PrecautionsView
The drug should be avoided if possible in patients with renal and hepatic failure and in those with heart block and myocardial disease. The drug may be used cautiously in pregnancy.
InteractionsView
Magnesium hydroxide can decrease the absorption of other drugs such as, digoxin, mycophenolate, phosphate supplements (e.g., potassium phosphate), tetracycline antibiotics, certain azole antifungals (ketoconazole, itraconazole), and quinolone antibiotics (e.g., ciprofloxacin, levofloxacin).
StorageView
Store in a cool & dry place, protected from light. Keep all medicines out of reach of children.
MagniLife DB
Apis mellifica + Gelsemium sempervirens + Gnaphalium
MagniLife DB
Apis mellifica + Gelsemium sempervirens + Gnaphalium
Indication detailsView
- Foot cream for pain relief
- Soothes damaged nerves and calms itchy and dry skin
- Intensely moisturizing to improve overall skin health
- Ideal for diabetics
- 100% safe to use between the toes
- Non-greasy formula that absorbs quickly
- Size: 4 ounces
PharmacologyView
Intense moisturizing treatment developed for severely dry, cracked, itchy and sensitive skin, softens hardened, callused skin to eliminate painful cracks and fissures, and relieves itching. Greaseless formula penetrates deeply. No added dyes, no petroleum or mineral oils. 100% safe to use between the toes.
DosageView
Generously apply and massage into all surfaces of the feet, heels, and toes twice daily. Apply to legs as needed.
PrecautionsView
- Keep null of reach of children
- For external use only
- Avoid contact with eyes
- If symptoms persist for more than 7 days or worsen, consult your physician
- Do not rise on open wounds, cuts, damaged, or infected skin
StorageView
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
Magnide
Magnesium Oxide
Magnide
Magnesium Oxide
Indication detailsView
Magnesium Oxide is indicated for the treatment of following condition:
- Relieving the symptoms of magnesium defciency
- Cardiovascular system: Rapid heartbeat, heart rate irregularity, heart attack, angina pectoris (chest pain caused by narrowing / obstruction of heart-feeding vessels), mild severe hypertension
- Nervous system and muscles: Sudden and excessive contractions (tetania) in the muscles, muscle cramp, gastrointestinal cramps, increased stimulability of muscles and nerves, calf cramps, cramp conditions in newborn and young children and stress
- Gynecological diseases, birth and pregnancy: Pre-term contraction, cervical insufciency, premature membrane rupture, contractions during pregnancy (eclampsia [Disease with seizures, blood pressure increase, protein in the urine, water retention in body during pregnancy]/preeclampsia [Disease with blood pressure increase, protein in the urine, water retention in body during pregnancy]), tocolysis requiring the use of beta mimetic (interruption of the uterine contractions), dysmenorrhea.
- Orthopedics: Calcifcation and ossifcation
- Prevention of kidney stone formation (prevention of recurrence of calcium oxalate urolithiasis)
- Diabetes treatment and migraine (a kind of headache)
Therapeutic classView
Antacids, Electrolytes preparations, Oral electrolytes preparations
PharmacologyView
Pharmacology: Magnesium is the second most abundant intracellular divalent cation and is a cofactor for more than 300 metabolic reactions in the body. These processes include protein synthesis, cellular energy production and storage, cell growth and reproduction, DNA and RNA synthesis, and stabilization of mitochondrial membranes. Magnesium is one of the minerals responsible for managing bone metabolism, nerve transmission, cardiac excitability, neuromuscular conduction, muscular contraction, vasomotor tone, and blood pressure. Magnesium also plays a significant role in glucose and insulin metabolism, mainly through its impact on tyrosine kinase activity, phosphorylase b kinase activity, and glucose transporter protein activity. Because of these vital roles, magnesium levels may be affected by stressors to the body, such as in certain disease states. Supplementation with magnesium may have therapeutic effects in these situations.
Pharmacokinetics: Absorption of a micronutrient as Mg is affected by other nutrients and reaches an estimated 30–50% of dietary Mg intake at basal conditions, while the absorption fraction declines with age and raising Mg intake. The drug absorption depends on both the kind of Mg salt and other food elements that may either augment or abate it. The distribution of Mg is mainly intracellular, <1% circulates in the blood (both extracellularly and intracellularly), and total serum Mg comprises three states with roughly 60% ionized, 33% protein-bound and 7% anion complexed. Elimination of Mg is handled by renal filtration with 25% being reabsorbed in the proximal convoluted tubule and further 50–60% is reabsorbed in the loop of Henle. Around 70–80% of plasma Mg undergoes glomerular filtration, but merely 3% is eventually excreted in the urine.
Pharmacokinetics: Absorption of a micronutrient as Mg is affected by other nutrients and reaches an estimated 30–50% of dietary Mg intake at basal conditions, while the absorption fraction declines with age and raising Mg intake. The drug absorption depends on both the kind of Mg salt and other food elements that may either augment or abate it. The distribution of Mg is mainly intracellular, <1% circulates in the blood (both extracellularly and intracellularly), and total serum Mg comprises three states with roughly 60% ionized, 33% protein-bound and 7% anion complexed. Elimination of Mg is handled by renal filtration with 25% being reabsorbed in the proximal convoluted tubule and further 50–60% is reabsorbed in the loop of Henle. Around 70–80% of plasma Mg undergoes glomerular filtration, but merely 3% is eventually excreted in the urine.
DosageView
Magnesium supplements must be taken with meal to reduce stomach upset and diarrhea. The recommended daily dose for adults and adolescents (12-17 years) is 1-2 tablets.
Kidney failure: Should not be used in patients with severe kidney insufficiency.
Liver failure: There are no data on patients with liver insufficiency.
Usage in the elderly: There is no data on the use in elderly patients.
Kidney failure: Should not be used in patients with severe kidney insufficiency.
Liver failure: There are no data on patients with liver insufficiency.
Usage in the elderly: There is no data on the use in elderly patients.
Side effectsView
Mild side effects include-Nausea, Vomiting, Diarrhea, Cramp, Tiredness, Weakness, Confusion. These side effects disappear when the dose is reduced or treatment is discontinued. Serious side effects include low blood pressure, changes in the recording of the heart's electrical activity (ECG), depression, severe allergic reaction (e.g. swelling in mouth and throat, itching, rash, redness), respiratory depression, coma. These may require emergency medical treatment. These serious side efects occur very rarely.
ContraindicationsView
Hypersensitivity and severe renal impairment.
PrecautionsView
This product may contain inactive ingredients, which can cause allergic reactions or other problems. If anyone has the following health problem, consult with doctor before using this product: kidney disease, alcohol dependence, liver disease, phenylketonuria (PKU), or any other condition that requires limit/avoid these substances from diet.
InteractionsView
Other medicines can affect treatment with Magnesium Oxide tablet. If you are using any of the following: medicines, tell your doctor; muscle relaxants (non-depolarizing neuromuscular blockers), aminoquinolones, nitrofurantoin, penicillamine, tetracyclines, fluoroquinolones (antibiotics), Digoxin (for the treatment of heart failure), Lithium (Control of emotional changes and depression), Sodium polystyrene sulfonate (allows potassium to be removed from the body), Cellulose sodium phosphate (used to prevent kidney stones), Other medicines containing magnesium (including magnesium enemas), Barbiturates (drugs used for the treatment of insomnia), opioids (substances that act as morphine in the body), hypnotics (soporific), Nifedipine (drugs used in high blood pressure or heart problems).
Pregnancy & lactationView
The recommended daily dose in pregnancy and lactation is 1-2 tablets. (During pregnancy & lactation, this product should be used only when clearly needed).
Overdose effectsView
Symptoms of overdose may include slow heartbeat, severe dizziness, confusion, muscle weakness, loss of consciousness, diarrhea and hypermagnesemia.
StorageView
Store below 25°C. Protected from light and moisture. Keep all medicines out of the reach of children.
Magnito
Magnesium Oxide
Magnito
Magnesium Oxide
Indication detailsView
Magnesium Oxide is indicated for the treatment of following condition:
- Relieving the symptoms of magnesium defciency
- Cardiovascular system: Rapid heartbeat, heart rate irregularity, heart attack, angina pectoris (chest pain caused by narrowing / obstruction of heart-feeding vessels), mild severe hypertension
- Nervous system and muscles: Sudden and excessive contractions (tetania) in the muscles, muscle cramp, gastrointestinal cramps, increased stimulability of muscles and nerves, calf cramps, cramp conditions in newborn and young children and stress
- Gynecological diseases, birth and pregnancy: Pre-term contraction, cervical insufciency, premature membrane rupture, contractions during pregnancy (eclampsia [Disease with seizures, blood pressure increase, protein in the urine, water retention in body during pregnancy]/preeclampsia [Disease with blood pressure increase, protein in the urine, water retention in body during pregnancy]), tocolysis requiring the use of beta mimetic (interruption of the uterine contractions), dysmenorrhea.
- Orthopedics: Calcifcation and ossifcation
- Prevention of kidney stone formation (prevention of recurrence of calcium oxalate urolithiasis)
- Diabetes treatment and migraine (a kind of headache)
Therapeutic classView
Antacids, Electrolytes preparations, Oral electrolytes preparations
PharmacologyView
Pharmacology: Magnesium is the second most abundant intracellular divalent cation and is a cofactor for more than 300 metabolic reactions in the body. These processes include protein synthesis, cellular energy production and storage, cell growth and reproduction, DNA and RNA synthesis, and stabilization of mitochondrial membranes. Magnesium is one of the minerals responsible for managing bone metabolism, nerve transmission, cardiac excitability, neuromuscular conduction, muscular contraction, vasomotor tone, and blood pressure. Magnesium also plays a significant role in glucose and insulin metabolism, mainly through its impact on tyrosine kinase activity, phosphorylase b kinase activity, and glucose transporter protein activity. Because of these vital roles, magnesium levels may be affected by stressors to the body, such as in certain disease states. Supplementation with magnesium may have therapeutic effects in these situations.
Pharmacokinetics: Absorption of a micronutrient as Mg is affected by other nutrients and reaches an estimated 30–50% of dietary Mg intake at basal conditions, while the absorption fraction declines with age and raising Mg intake. The drug absorption depends on both the kind of Mg salt and other food elements that may either augment or abate it. The distribution of Mg is mainly intracellular, <1% circulates in the blood (both extracellularly and intracellularly), and total serum Mg comprises three states with roughly 60% ionized, 33% protein-bound and 7% anion complexed. Elimination of Mg is handled by renal filtration with 25% being reabsorbed in the proximal convoluted tubule and further 50–60% is reabsorbed in the loop of Henle. Around 70–80% of plasma Mg undergoes glomerular filtration, but merely 3% is eventually excreted in the urine.
Pharmacokinetics: Absorption of a micronutrient as Mg is affected by other nutrients and reaches an estimated 30–50% of dietary Mg intake at basal conditions, while the absorption fraction declines with age and raising Mg intake. The drug absorption depends on both the kind of Mg salt and other food elements that may either augment or abate it. The distribution of Mg is mainly intracellular, <1% circulates in the blood (both extracellularly and intracellularly), and total serum Mg comprises three states with roughly 60% ionized, 33% protein-bound and 7% anion complexed. Elimination of Mg is handled by renal filtration with 25% being reabsorbed in the proximal convoluted tubule and further 50–60% is reabsorbed in the loop of Henle. Around 70–80% of plasma Mg undergoes glomerular filtration, but merely 3% is eventually excreted in the urine.
DosageView
Magnesium supplements must be taken with meal to reduce stomach upset and diarrhea. The recommended daily dose for adults and adolescents (12-17 years) is 1-2 tablets.
Kidney failure: Should not be used in patients with severe kidney insufficiency.
Liver failure: There are no data on patients with liver insufficiency.
Usage in the elderly: There is no data on the use in elderly patients.
Kidney failure: Should not be used in patients with severe kidney insufficiency.
Liver failure: There are no data on patients with liver insufficiency.
Usage in the elderly: There is no data on the use in elderly patients.
Side effectsView
Mild side effects include-Nausea, Vomiting, Diarrhea, Cramp, Tiredness, Weakness, Confusion. These side effects disappear when the dose is reduced or treatment is discontinued. Serious side effects include low blood pressure, changes in the recording of the heart's electrical activity (ECG), depression, severe allergic reaction (e.g. swelling in mouth and throat, itching, rash, redness), respiratory depression, coma. These may require emergency medical treatment. These serious side efects occur very rarely.
ContraindicationsView
Hypersensitivity and severe renal impairment.
PrecautionsView
This product may contain inactive ingredients, which can cause allergic reactions or other problems. If anyone has the following health problem, consult with doctor before using this product: kidney disease, alcohol dependence, liver disease, phenylketonuria (PKU), or any other condition that requires limit/avoid these substances from diet.
InteractionsView
Other medicines can affect treatment with Magnesium Oxide tablet. If you are using any of the following: medicines, tell your doctor; muscle relaxants (non-depolarizing neuromuscular blockers), aminoquinolones, nitrofurantoin, penicillamine, tetracyclines, fluoroquinolones (antibiotics), Digoxin (for the treatment of heart failure), Lithium (Control of emotional changes and depression), Sodium polystyrene sulfonate (allows potassium to be removed from the body), Cellulose sodium phosphate (used to prevent kidney stones), Other medicines containing magnesium (including magnesium enemas), Barbiturates (drugs used for the treatment of insomnia), opioids (substances that act as morphine in the body), hypnotics (soporific), Nifedipine (drugs used in high blood pressure or heart problems).
Pregnancy & lactationView
The recommended daily dose in pregnancy and lactation is 1-2 tablets. (During pregnancy & lactation, this product should be used only when clearly needed).
Overdose effectsView
Symptoms of overdose may include slow heartbeat, severe dizziness, confusion, muscle weakness, loss of consciousness, diarrhea and hypermagnesemia.
StorageView
Store below 25°C. Protected from light and moisture. Keep all medicines out of the reach of children.
Magnogel
Aluminium Hydroxide + Magnesium Hydroxide
Magnogel
Aluminium Hydroxide + Magnesium Hydroxide
Indications
Upper Gl bloating
Indication detailsView
Aluminium Hydroxide and Magnesium Hydroxide is indicated for Hyperacidity, peptic ulcer, gastritis, heartburn, sour stomach & dyspepsia.
Therapeutic classView
Antacids
PharmacologyView
This drug is well-balanced combination of essential non-systemic antacids which excel in efficacy and palatability. These are dependable antacid preparations without acid rebound, constipating or cathertic effects. Both the preparations provide symptomatic relief of hyperacidity associated with heartburn, acid ingestion or sour stomach.
Aluminium hydroxide gel, a slow acting antacid and an adsorbent with prolonged effect, has high neutralizing power. Magnesium Hydroxide possesses a slow but sustained acid neutralizing property. Antacids of both tablet and suspension possess adsorbent property. They form a protecting coating over the ulcer surface facilitating its healing; thus protecting the sensitive mucosa of stomach and duodenum from further irritation.
Aluminium hydroxide gel, a slow acting antacid and an adsorbent with prolonged effect, has high neutralizing power. Magnesium Hydroxide possesses a slow but sustained acid neutralizing property. Antacids of both tablet and suspension possess adsorbent property. They form a protecting coating over the ulcer surface facilitating its healing; thus protecting the sensitive mucosa of stomach and duodenum from further irritation.
DosageView
Tablet: Two tablets 1-3 hours after meal and at bed time or as directed by the physician.
Suspension: 2 tea spoonful 1-3 hours after meal and at bed time or as directed by the physician.
Suspension: 2 tea spoonful 1-3 hours after meal and at bed time or as directed by the physician.
Side effectsView
Long term use of any antacid results in alkaluria, which may predispose to nephrolithiasis by forming precipitation of calcium phosphate.
ContraindicationsView
This is contraindicated in hypophosphataemia. It is also contraindicated in alkalosis and hypermagnesaemia where abdominal distention may be due to partial or complete intestinal obstruction.
PrecautionsView
Antacids reduce the absorption of tetracycline when given concomitantly. These should not be used concomitantly
InteractionsView
This drug inhibits the absorption of following drugs: Azithromycin, cefpodoxime, ciprofloxacin, isoniazid, rifampicin, norfloxacin, ofloxacin, pivampicillin, tetracyclines, Gabapentin and phenytoin, Itraconazole, ketoconazole, Chloroquine, hydroxychloroquine and Phenothiazines.
Pregnancy & lactationView
It is advised to avoid antacid preparations in the first trimester of pregnancy.
StorageView
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
Magnogel
Aluminium Hydroxide + Magnesium Hydroxide
Magnogel
Aluminium Hydroxide + Magnesium Hydroxide
Indications
Upper Gl bloating
Indication detailsView
Aluminium Hydroxide and Magnesium Hydroxide is indicated for Hyperacidity, peptic ulcer, gastritis, heartburn, sour stomach & dyspepsia.
Therapeutic classView
Antacids
PharmacologyView
This drug is well-balanced combination of essential non-systemic antacids which excel in efficacy and palatability. These are dependable antacid preparations without acid rebound, constipating or cathertic effects. Both the preparations provide symptomatic relief of hyperacidity associated with heartburn, acid ingestion or sour stomach.
Aluminium hydroxide gel, a slow acting antacid and an adsorbent with prolonged effect, has high neutralizing power. Magnesium Hydroxide possesses a slow but sustained acid neutralizing property. Antacids of both tablet and suspension possess adsorbent property. They form a protecting coating over the ulcer surface facilitating its healing; thus protecting the sensitive mucosa of stomach and duodenum from further irritation.
Aluminium hydroxide gel, a slow acting antacid and an adsorbent with prolonged effect, has high neutralizing power. Magnesium Hydroxide possesses a slow but sustained acid neutralizing property. Antacids of both tablet and suspension possess adsorbent property. They form a protecting coating over the ulcer surface facilitating its healing; thus protecting the sensitive mucosa of stomach and duodenum from further irritation.
DosageView
Tablet: Two tablets 1-3 hours after meal and at bed time or as directed by the physician.
Suspension: 2 tea spoonful 1-3 hours after meal and at bed time or as directed by the physician.
Suspension: 2 tea spoonful 1-3 hours after meal and at bed time or as directed by the physician.
Side effectsView
Long term use of any antacid results in alkaluria, which may predispose to nephrolithiasis by forming precipitation of calcium phosphate.
ContraindicationsView
This is contraindicated in hypophosphataemia. It is also contraindicated in alkalosis and hypermagnesaemia where abdominal distention may be due to partial or complete intestinal obstruction.
PrecautionsView
Antacids reduce the absorption of tetracycline when given concomitantly. These should not be used concomitantly
InteractionsView
This drug inhibits the absorption of following drugs: Azithromycin, cefpodoxime, ciprofloxacin, isoniazid, rifampicin, norfloxacin, ofloxacin, pivampicillin, tetracyclines, Gabapentin and phenytoin, Itraconazole, ketoconazole, Chloroquine, hydroxychloroquine and Phenothiazines.
Pregnancy & lactationView
It is advised to avoid antacid preparations in the first trimester of pregnancy.
StorageView
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
Magnova
Cefepime Hydrochloride
Magnova
Cefepime Hydrochloride
Indications
Urinary tract infection
Indication detailsView
Cefepime is indicated for the treatment of the following infections caused by susceptible strains of the microorganisms:
- Pneumonia (moderate to severe): caused by Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aeruginosa, Klebsiella pneumoniae, or Enterobacter species.
- Febrile Neutropenia: Cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients.
- Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis): caused by Escherichia coli or Klebsiella pneumoniae, when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis, when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms.
- Uncomplicated Skin and Skin Structure Infections: caused by Staphylococcus aureus (methicillin- susceptible strains only) or Streptococcus pyogenes.
- Complicated Intra-abdominal Infections (used in combination with metronidazole): caused by Escherichia coli, viridians group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter species, or Bacteroides fragilis.
Therapeutic classView
Fourth generation Cephalosporins
PharmacologyView
Cephalosporins are bactericidal and have the same mode of action as other beta-lactam antibiotics (such as penicillins). Cephalosporins disrupt the synthesis of the peptidoglycan layer of bacterial cell walls. The peptidoglycan layer is important for cell wall structural integrity, especially in Gram-positive organisms. The final transpeptidation step in the synthesis of the peptidoglycan is facilitated by transpeptidases known as penicillin binding proteins (PBPs).
DosageView
Cefepime should be administered intravenously over approximately 30 minutes.
*including cases associated with concurrent bacteremia.
**or until resolution of neutropenia. In patients whose fever resolves but who remain neutropenic for more than 7 days, the need for continued antimicrobial therapy should be re evaluated frequently.
*** IM route of administration is indicated only for mild to moderate, uncomplicated or complicated UTls due to E. coli when the IM route is considered to be a more appropriate route of drug administration.
- Moderate to Severe Pneumonia due to S. pneumoniae, *P. aeruginosa, K. pneumoniae, or Enterobacter species: 1-2 gm IV 12 hourly for 10 days.
- Empiric therapy for febrile neutropenic patients: 2 gm IV 8 hourly for 7** days.
- Mild to Moderate Uncomplicated or Complicated Urinary Tract Infections, including pyelonephritis, due to E. coli, K. pneumoniae, or P. mirabilis*: 0.5-1 gm IV/IM*** 12 hourly for 7-10 days.
- Severe Uncomplicated or Complicated Urinary Tract Infections, including pyelonephritis, due to E. coli or K. pneumoniae*: 2 gm IV 12 hourly for 10 days.
- Moderate to Severe Uncomplicated Skin and Skin Structure Infections due to S. aureus or S. pyogenes: 2 gm IV 12 hourly for 10 days.
- Complicated Intra-abdominal Infections (used in combination with metronidazole) caused by E. coli, viridans group streptococci, P. aeruginosa, K. pneumoniae, Enterobacter species, or B. fragilis: 2 gm IV 12 hourly for 7-10 days.
*including cases associated with concurrent bacteremia.
**or until resolution of neutropenia. In patients whose fever resolves but who remain neutropenic for more than 7 days, the need for continued antimicrobial therapy should be re evaluated frequently.
*** IM route of administration is indicated only for mild to moderate, uncomplicated or complicated UTls due to E. coli when the IM route is considered to be a more appropriate route of drug administration.
Side effectsView
Cefepime is contraindicated in patients who have shown immediate hypersensitivity reactions to cefepime or the cephalosporin class of antibiotics, penicillin, or other betalactum antibiotics.
ContraindicationsView
Cefepime is contraindicated in patients who have shown immediate hypersensitivity reactions to cefepime or the cephalosporin class of antibiotics, penicillin, or other betalactum antibiotics.
PrecautionsView
- Prescribing Cefepime in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
- As with other antimicrobials, prolonged use of Cefepime may result in overgrowth of non susceptible microorganisms. Repeated evaluation of the patient's condition is essential.
- Many cephalosporins, including cefepime, have been associated with a fall in prothrombin activity. Those at risk include patients with renal or hepatic impairment, or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy. Prothrombin time should be monitored in patients at risk.
- Cefepime should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.
- Arginine has been shown to alter glucose metabolism and elevate serum potassium transiently when administered at 33 times the amount provided by the maximum recommended human dose of Cefepime. The effect of lower doses is not presently known.
InteractionsView
Renal function should be monitored carefully if high doses of aminoglycosides are to be administered with Cefepime because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibiotics. Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.
Pregnancy & lactationView
Pregnancy Category B. There are, however, no adequate and well-controlled studies of cefepime use in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Cefepime is excreted in human breast milk in very low concentrations (0.5 pg/ml). Caution should be exercised when cefepime is administered to a nursing woman.
Pediatric usageView
Pediatric Use (2 months up to 16 years): The maximum dose for pediatric patients should not exceed the recommended adult dose. The usual recommended dosage in pediatric patients up to 40 kg in weight for uncomplicated and complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin structure infections, and pneumonia is 50 mg/kg/dose, administered every 12 hours (50 mg/kg/dose, every 8 hours for febrile neutropenic patients), for durations as given above.
Geriatric Use: Serious adverse events have occurred in geriatric patients with renal insufficiency given unadjusted doses of cefepime, including life-threatening or fatal occurrences of the following: encephalopathy, myoclonus, and seizures. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and renal function should be monitored.
Impaired Hepatic Function: No adjustment is necessary for patients with impaired hepatic function.
Impaired Renal Function: In patients with impaired renal function (creatinine clearance<60 ml/min), the dose of Cefepime should be adjusted to compensate for the slower rate of renal elimination.
Geriatric Use: Serious adverse events have occurred in geriatric patients with renal insufficiency given unadjusted doses of cefepime, including life-threatening or fatal occurrences of the following: encephalopathy, myoclonus, and seizures. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and renal function should be monitored.
Impaired Hepatic Function: No adjustment is necessary for patients with impaired hepatic function.
Impaired Renal Function: In patients with impaired renal function (creatinine clearance<60 ml/min), the dose of Cefepime should be adjusted to compensate for the slower rate of renal elimination.
Overdose effectsView
Patients who receive an overdose should be carefully observed and given supportive treatment. In the presence of renal insufficiency, hemodialysis, not peritoneal dialysis, is recommended to aid the removal of cefepime from the body. Accidental overdosing has occurred when large doses were given to patients with impaired renal function. Symptoms of overdose include encephalopathy (disturbance of consciousness including confusion, hallucinations, stupor, and coma), myoclonus, seizures, and neuromuscular excitability.
ReconstitutionView
For IV the resulting solution should be injected directly into the vein over a period of three to five minutes or injected into the tubing of an administration set while the patient is receiving a compatible IV fluid.
Intravenous: Cefepime is compatible with Sterile Water for Injection. It is also compatible at concentrations between 1 mg/ml and 40 mg/ml with the following IV infusion fluids: 0.9% Sodium Chloride Injection, 5% and 10% Dextrose Injection, M/6 Sodium Lactate Injection, 5% Dextrose and 0.9% Sodium Chloride Injection, Lactated Ringers and 5% Dextrose Injection.
Intramuscular: Cefepime is compatible with the following diluent such as: Sterile Water for Injection, 0.9% Sodium Chloride Injection, 5% Dextrose Injection, Sterile Bacteriostatic Water for Injection with Parabens or Benzyl Alcohol or 0.5% or 1% Lidocaine Hydrochloride.
500 mg (IV) vials for intravenous administration:
Intravenous: Cefepime is compatible with Sterile Water for Injection. It is also compatible at concentrations between 1 mg/ml and 40 mg/ml with the following IV infusion fluids: 0.9% Sodium Chloride Injection, 5% and 10% Dextrose Injection, M/6 Sodium Lactate Injection, 5% Dextrose and 0.9% Sodium Chloride Injection, Lactated Ringers and 5% Dextrose Injection.
Intramuscular: Cefepime is compatible with the following diluent such as: Sterile Water for Injection, 0.9% Sodium Chloride Injection, 5% Dextrose Injection, Sterile Bacteriostatic Water for Injection with Parabens or Benzyl Alcohol or 0.5% or 1% Lidocaine Hydrochloride.
500 mg (IV) vials for intravenous administration:
- Amount of WFI to be added: 5 ml
- Approximate available volume: 5.6 ml
- Amount of WFI to be added: 1.3 ml
- Approximate available volume: 1.8 ml
- Amount of WFI to be added: 10 ml
- Approximate available volume: 11.3 ml
- Amount of WFI to be added: 2.4 ml
- Approximate available volume: 3.6 ml
- Amount of WFI to be added: 10 ml
- Approximate available volume: 12.5 ml
StorageView
Do not use later than the date of expiry. Keep all medicines out of the reach of children. To be dispensed only on the prescription of a registered physician.
Magnova
Cefepime Hydrochloride
Magnova
Cefepime Hydrochloride
Indications
Urinary tract infection
Indication detailsView
Cefepime is indicated for the treatment of the following infections caused by susceptible strains of the microorganisms:
- Pneumonia (moderate to severe): caused by Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aeruginosa, Klebsiella pneumoniae, or Enterobacter species.
- Febrile Neutropenia: Cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients.
- Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis): caused by Escherichia coli or Klebsiella pneumoniae, when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis, when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms.
- Uncomplicated Skin and Skin Structure Infections: caused by Staphylococcus aureus (methicillin- susceptible strains only) or Streptococcus pyogenes.
- Complicated Intra-abdominal Infections (used in combination with metronidazole): caused by Escherichia coli, viridians group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter species, or Bacteroides fragilis.
Therapeutic classView
Fourth generation Cephalosporins
PharmacologyView
Cephalosporins are bactericidal and have the same mode of action as other beta-lactam antibiotics (such as penicillins). Cephalosporins disrupt the synthesis of the peptidoglycan layer of bacterial cell walls. The peptidoglycan layer is important for cell wall structural integrity, especially in Gram-positive organisms. The final transpeptidation step in the synthesis of the peptidoglycan is facilitated by transpeptidases known as penicillin binding proteins (PBPs).
DosageView
Cefepime should be administered intravenously over approximately 30 minutes.
*including cases associated with concurrent bacteremia.
**or until resolution of neutropenia. In patients whose fever resolves but who remain neutropenic for more than 7 days, the need for continued antimicrobial therapy should be re evaluated frequently.
*** IM route of administration is indicated only for mild to moderate, uncomplicated or complicated UTls due to E. coli when the IM route is considered to be a more appropriate route of drug administration.
- Moderate to Severe Pneumonia due to S. pneumoniae, *P. aeruginosa, K. pneumoniae, or Enterobacter species: 1-2 gm IV 12 hourly for 10 days.
- Empiric therapy for febrile neutropenic patients: 2 gm IV 8 hourly for 7** days.
- Mild to Moderate Uncomplicated or Complicated Urinary Tract Infections, including pyelonephritis, due to E. coli, K. pneumoniae, or P. mirabilis*: 0.5-1 gm IV/IM*** 12 hourly for 7-10 days.
- Severe Uncomplicated or Complicated Urinary Tract Infections, including pyelonephritis, due to E. coli or K. pneumoniae*: 2 gm IV 12 hourly for 10 days.
- Moderate to Severe Uncomplicated Skin and Skin Structure Infections due to S. aureus or S. pyogenes: 2 gm IV 12 hourly for 10 days.
- Complicated Intra-abdominal Infections (used in combination with metronidazole) caused by E. coli, viridans group streptococci, P. aeruginosa, K. pneumoniae, Enterobacter species, or B. fragilis: 2 gm IV 12 hourly for 7-10 days.
*including cases associated with concurrent bacteremia.
**or until resolution of neutropenia. In patients whose fever resolves but who remain neutropenic for more than 7 days, the need for continued antimicrobial therapy should be re evaluated frequently.
*** IM route of administration is indicated only for mild to moderate, uncomplicated or complicated UTls due to E. coli when the IM route is considered to be a more appropriate route of drug administration.
Side effectsView
Cefepime is contraindicated in patients who have shown immediate hypersensitivity reactions to cefepime or the cephalosporin class of antibiotics, penicillin, or other betalactum antibiotics.
ContraindicationsView
Cefepime is contraindicated in patients who have shown immediate hypersensitivity reactions to cefepime or the cephalosporin class of antibiotics, penicillin, or other betalactum antibiotics.
PrecautionsView
- Prescribing Cefepime in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
- As with other antimicrobials, prolonged use of Cefepime may result in overgrowth of non susceptible microorganisms. Repeated evaluation of the patient's condition is essential.
- Many cephalosporins, including cefepime, have been associated with a fall in prothrombin activity. Those at risk include patients with renal or hepatic impairment, or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy. Prothrombin time should be monitored in patients at risk.
- Cefepime should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.
- Arginine has been shown to alter glucose metabolism and elevate serum potassium transiently when administered at 33 times the amount provided by the maximum recommended human dose of Cefepime. The effect of lower doses is not presently known.
InteractionsView
Renal function should be monitored carefully if high doses of aminoglycosides are to be administered with Cefepime because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibiotics. Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.
Pregnancy & lactationView
Pregnancy Category B. There are, however, no adequate and well-controlled studies of cefepime use in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Cefepime is excreted in human breast milk in very low concentrations (0.5 pg/ml). Caution should be exercised when cefepime is administered to a nursing woman.
Pediatric usageView
Pediatric Use (2 months up to 16 years): The maximum dose for pediatric patients should not exceed the recommended adult dose. The usual recommended dosage in pediatric patients up to 40 kg in weight for uncomplicated and complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin structure infections, and pneumonia is 50 mg/kg/dose, administered every 12 hours (50 mg/kg/dose, every 8 hours for febrile neutropenic patients), for durations as given above.
Geriatric Use: Serious adverse events have occurred in geriatric patients with renal insufficiency given unadjusted doses of cefepime, including life-threatening or fatal occurrences of the following: encephalopathy, myoclonus, and seizures. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and renal function should be monitored.
Impaired Hepatic Function: No adjustment is necessary for patients with impaired hepatic function.
Impaired Renal Function: In patients with impaired renal function (creatinine clearance<60 ml/min), the dose of Cefepime should be adjusted to compensate for the slower rate of renal elimination.
Geriatric Use: Serious adverse events have occurred in geriatric patients with renal insufficiency given unadjusted doses of cefepime, including life-threatening or fatal occurrences of the following: encephalopathy, myoclonus, and seizures. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and renal function should be monitored.
Impaired Hepatic Function: No adjustment is necessary for patients with impaired hepatic function.
Impaired Renal Function: In patients with impaired renal function (creatinine clearance<60 ml/min), the dose of Cefepime should be adjusted to compensate for the slower rate of renal elimination.
Overdose effectsView
Patients who receive an overdose should be carefully observed and given supportive treatment. In the presence of renal insufficiency, hemodialysis, not peritoneal dialysis, is recommended to aid the removal of cefepime from the body. Accidental overdosing has occurred when large doses were given to patients with impaired renal function. Symptoms of overdose include encephalopathy (disturbance of consciousness including confusion, hallucinations, stupor, and coma), myoclonus, seizures, and neuromuscular excitability.
ReconstitutionView
For IV the resulting solution should be injected directly into the vein over a period of three to five minutes or injected into the tubing of an administration set while the patient is receiving a compatible IV fluid.
Intravenous: Cefepime is compatible with Sterile Water for Injection. It is also compatible at concentrations between 1 mg/ml and 40 mg/ml with the following IV infusion fluids: 0.9% Sodium Chloride Injection, 5% and 10% Dextrose Injection, M/6 Sodium Lactate Injection, 5% Dextrose and 0.9% Sodium Chloride Injection, Lactated Ringers and 5% Dextrose Injection.
Intramuscular: Cefepime is compatible with the following diluent such as: Sterile Water for Injection, 0.9% Sodium Chloride Injection, 5% Dextrose Injection, Sterile Bacteriostatic Water for Injection with Parabens or Benzyl Alcohol or 0.5% or 1% Lidocaine Hydrochloride.
500 mg (IV) vials for intravenous administration:
Intravenous: Cefepime is compatible with Sterile Water for Injection. It is also compatible at concentrations between 1 mg/ml and 40 mg/ml with the following IV infusion fluids: 0.9% Sodium Chloride Injection, 5% and 10% Dextrose Injection, M/6 Sodium Lactate Injection, 5% Dextrose and 0.9% Sodium Chloride Injection, Lactated Ringers and 5% Dextrose Injection.
Intramuscular: Cefepime is compatible with the following diluent such as: Sterile Water for Injection, 0.9% Sodium Chloride Injection, 5% Dextrose Injection, Sterile Bacteriostatic Water for Injection with Parabens or Benzyl Alcohol or 0.5% or 1% Lidocaine Hydrochloride.
500 mg (IV) vials for intravenous administration:
- Amount of WFI to be added: 5 ml
- Approximate available volume: 5.6 ml
- Amount of WFI to be added: 1.3 ml
- Approximate available volume: 1.8 ml
- Amount of WFI to be added: 10 ml
- Approximate available volume: 11.3 ml
- Amount of WFI to be added: 2.4 ml
- Approximate available volume: 3.6 ml
- Amount of WFI to be added: 10 ml
- Approximate available volume: 12.5 ml
StorageView
Do not use later than the date of expiry. Keep all medicines out of the reach of children. To be dispensed only on the prescription of a registered physician.
Magnox
Magnesium Oxide
Magnox
Magnesium Oxide
Indication detailsView
Magnesium Oxide is indicated for the treatment of following condition:
- Relieving the symptoms of magnesium defciency
- Cardiovascular system: Rapid heartbeat, heart rate irregularity, heart attack, angina pectoris (chest pain caused by narrowing / obstruction of heart-feeding vessels), mild severe hypertension
- Nervous system and muscles: Sudden and excessive contractions (tetania) in the muscles, muscle cramp, gastrointestinal cramps, increased stimulability of muscles and nerves, calf cramps, cramp conditions in newborn and young children and stress
- Gynecological diseases, birth and pregnancy: Pre-term contraction, cervical insufciency, premature membrane rupture, contractions during pregnancy (eclampsia [Disease with seizures, blood pressure increase, protein in the urine, water retention in body during pregnancy]/preeclampsia [Disease with blood pressure increase, protein in the urine, water retention in body during pregnancy]), tocolysis requiring the use of beta mimetic (interruption of the uterine contractions), dysmenorrhea.
- Orthopedics: Calcifcation and ossifcation
- Prevention of kidney stone formation (prevention of recurrence of calcium oxalate urolithiasis)
- Diabetes treatment and migraine (a kind of headache)
Therapeutic classView
Antacids, Electrolytes preparations, Oral electrolytes preparations
PharmacologyView
Pharmacology: Magnesium is the second most abundant intracellular divalent cation and is a cofactor for more than 300 metabolic reactions in the body. These processes include protein synthesis, cellular energy production and storage, cell growth and reproduction, DNA and RNA synthesis, and stabilization of mitochondrial membranes. Magnesium is one of the minerals responsible for managing bone metabolism, nerve transmission, cardiac excitability, neuromuscular conduction, muscular contraction, vasomotor tone, and blood pressure. Magnesium also plays a significant role in glucose and insulin metabolism, mainly through its impact on tyrosine kinase activity, phosphorylase b kinase activity, and glucose transporter protein activity. Because of these vital roles, magnesium levels may be affected by stressors to the body, such as in certain disease states. Supplementation with magnesium may have therapeutic effects in these situations.
Pharmacokinetics: Absorption of a micronutrient as Mg is affected by other nutrients and reaches an estimated 30–50% of dietary Mg intake at basal conditions, while the absorption fraction declines with age and raising Mg intake. The drug absorption depends on both the kind of Mg salt and other food elements that may either augment or abate it. The distribution of Mg is mainly intracellular, <1% circulates in the blood (both extracellularly and intracellularly), and total serum Mg comprises three states with roughly 60% ionized, 33% protein-bound and 7% anion complexed. Elimination of Mg is handled by renal filtration with 25% being reabsorbed in the proximal convoluted tubule and further 50–60% is reabsorbed in the loop of Henle. Around 70–80% of plasma Mg undergoes glomerular filtration, but merely 3% is eventually excreted in the urine.
Pharmacokinetics: Absorption of a micronutrient as Mg is affected by other nutrients and reaches an estimated 30–50% of dietary Mg intake at basal conditions, while the absorption fraction declines with age and raising Mg intake. The drug absorption depends on both the kind of Mg salt and other food elements that may either augment or abate it. The distribution of Mg is mainly intracellular, <1% circulates in the blood (both extracellularly and intracellularly), and total serum Mg comprises three states with roughly 60% ionized, 33% protein-bound and 7% anion complexed. Elimination of Mg is handled by renal filtration with 25% being reabsorbed in the proximal convoluted tubule and further 50–60% is reabsorbed in the loop of Henle. Around 70–80% of plasma Mg undergoes glomerular filtration, but merely 3% is eventually excreted in the urine.
DosageView
Magnesium supplements must be taken with meal to reduce stomach upset and diarrhea. The recommended daily dose for adults and adolescents (12-17 years) is 1-2 tablets.
Kidney failure: Should not be used in patients with severe kidney insufficiency.
Liver failure: There are no data on patients with liver insufficiency.
Usage in the elderly: There is no data on the use in elderly patients.
Kidney failure: Should not be used in patients with severe kidney insufficiency.
Liver failure: There are no data on patients with liver insufficiency.
Usage in the elderly: There is no data on the use in elderly patients.
Side effectsView
Mild side effects include-Nausea, Vomiting, Diarrhea, Cramp, Tiredness, Weakness, Confusion. These side effects disappear when the dose is reduced or treatment is discontinued. Serious side effects include low blood pressure, changes in the recording of the heart's electrical activity (ECG), depression, severe allergic reaction (e.g. swelling in mouth and throat, itching, rash, redness), respiratory depression, coma. These may require emergency medical treatment. These serious side efects occur very rarely.
ContraindicationsView
Hypersensitivity and severe renal impairment.
PrecautionsView
This product may contain inactive ingredients, which can cause allergic reactions or other problems. If anyone has the following health problem, consult with doctor before using this product: kidney disease, alcohol dependence, liver disease, phenylketonuria (PKU), or any other condition that requires limit/avoid these substances from diet.
InteractionsView
Other medicines can affect treatment with Magnesium Oxide tablet. If you are using any of the following: medicines, tell your doctor; muscle relaxants (non-depolarizing neuromuscular blockers), aminoquinolones, nitrofurantoin, penicillamine, tetracyclines, fluoroquinolones (antibiotics), Digoxin (for the treatment of heart failure), Lithium (Control of emotional changes and depression), Sodium polystyrene sulfonate (allows potassium to be removed from the body), Cellulose sodium phosphate (used to prevent kidney stones), Other medicines containing magnesium (including magnesium enemas), Barbiturates (drugs used for the treatment of insomnia), opioids (substances that act as morphine in the body), hypnotics (soporific), Nifedipine (drugs used in high blood pressure or heart problems).
Pregnancy & lactationView
The recommended daily dose in pregnancy and lactation is 1-2 tablets. (During pregnancy & lactation, this product should be used only when clearly needed).
Overdose effectsView
Symptoms of overdose may include slow heartbeat, severe dizziness, confusion, muscle weakness, loss of consciousness, diarrhea and hypermagnesemia.
StorageView
Store below 25°C. Protected from light and moisture. Keep all medicines out of the reach of children.
Magnum
Magnesium Oxide
Magnum
Magnesium Oxide
Indication detailsView
Magnesium Oxide is indicated for the treatment of following condition:
- Relieving the symptoms of magnesium defciency
- Cardiovascular system: Rapid heartbeat, heart rate irregularity, heart attack, angina pectoris (chest pain caused by narrowing / obstruction of heart-feeding vessels), mild severe hypertension
- Nervous system and muscles: Sudden and excessive contractions (tetania) in the muscles, muscle cramp, gastrointestinal cramps, increased stimulability of muscles and nerves, calf cramps, cramp conditions in newborn and young children and stress
- Gynecological diseases, birth and pregnancy: Pre-term contraction, cervical insufciency, premature membrane rupture, contractions during pregnancy (eclampsia [Disease with seizures, blood pressure increase, protein in the urine, water retention in body during pregnancy]/preeclampsia [Disease with blood pressure increase, protein in the urine, water retention in body during pregnancy]), tocolysis requiring the use of beta mimetic (interruption of the uterine contractions), dysmenorrhea.
- Orthopedics: Calcifcation and ossifcation
- Prevention of kidney stone formation (prevention of recurrence of calcium oxalate urolithiasis)
- Diabetes treatment and migraine (a kind of headache)
Therapeutic classView
Antacids, Electrolytes preparations, Oral electrolytes preparations
PharmacologyView
Pharmacology: Magnesium is the second most abundant intracellular divalent cation and is a cofactor for more than 300 metabolic reactions in the body. These processes include protein synthesis, cellular energy production and storage, cell growth and reproduction, DNA and RNA synthesis, and stabilization of mitochondrial membranes. Magnesium is one of the minerals responsible for managing bone metabolism, nerve transmission, cardiac excitability, neuromuscular conduction, muscular contraction, vasomotor tone, and blood pressure. Magnesium also plays a significant role in glucose and insulin metabolism, mainly through its impact on tyrosine kinase activity, phosphorylase b kinase activity, and glucose transporter protein activity. Because of these vital roles, magnesium levels may be affected by stressors to the body, such as in certain disease states. Supplementation with magnesium may have therapeutic effects in these situations.
Pharmacokinetics: Absorption of a micronutrient as Mg is affected by other nutrients and reaches an estimated 30–50% of dietary Mg intake at basal conditions, while the absorption fraction declines with age and raising Mg intake. The drug absorption depends on both the kind of Mg salt and other food elements that may either augment or abate it. The distribution of Mg is mainly intracellular, <1% circulates in the blood (both extracellularly and intracellularly), and total serum Mg comprises three states with roughly 60% ionized, 33% protein-bound and 7% anion complexed. Elimination of Mg is handled by renal filtration with 25% being reabsorbed in the proximal convoluted tubule and further 50–60% is reabsorbed in the loop of Henle. Around 70–80% of plasma Mg undergoes glomerular filtration, but merely 3% is eventually excreted in the urine.
Pharmacokinetics: Absorption of a micronutrient as Mg is affected by other nutrients and reaches an estimated 30–50% of dietary Mg intake at basal conditions, while the absorption fraction declines with age and raising Mg intake. The drug absorption depends on both the kind of Mg salt and other food elements that may either augment or abate it. The distribution of Mg is mainly intracellular, <1% circulates in the blood (both extracellularly and intracellularly), and total serum Mg comprises three states with roughly 60% ionized, 33% protein-bound and 7% anion complexed. Elimination of Mg is handled by renal filtration with 25% being reabsorbed in the proximal convoluted tubule and further 50–60% is reabsorbed in the loop of Henle. Around 70–80% of plasma Mg undergoes glomerular filtration, but merely 3% is eventually excreted in the urine.
DosageView
Magnesium supplements must be taken with meal to reduce stomach upset and diarrhea. The recommended daily dose for adults and adolescents (12-17 years) is 1-2 tablets.
Kidney failure: Should not be used in patients with severe kidney insufficiency.
Liver failure: There are no data on patients with liver insufficiency.
Usage in the elderly: There is no data on the use in elderly patients.
Kidney failure: Should not be used in patients with severe kidney insufficiency.
Liver failure: There are no data on patients with liver insufficiency.
Usage in the elderly: There is no data on the use in elderly patients.
Side effectsView
Mild side effects include-Nausea, Vomiting, Diarrhea, Cramp, Tiredness, Weakness, Confusion. These side effects disappear when the dose is reduced or treatment is discontinued. Serious side effects include low blood pressure, changes in the recording of the heart's electrical activity (ECG), depression, severe allergic reaction (e.g. swelling in mouth and throat, itching, rash, redness), respiratory depression, coma. These may require emergency medical treatment. These serious side efects occur very rarely.
ContraindicationsView
Hypersensitivity and severe renal impairment.
PrecautionsView
This product may contain inactive ingredients, which can cause allergic reactions or other problems. If anyone has the following health problem, consult with doctor before using this product: kidney disease, alcohol dependence, liver disease, phenylketonuria (PKU), or any other condition that requires limit/avoid these substances from diet.
InteractionsView
Other medicines can affect treatment with Magnesium Oxide tablet. If you are using any of the following: medicines, tell your doctor; muscle relaxants (non-depolarizing neuromuscular blockers), aminoquinolones, nitrofurantoin, penicillamine, tetracyclines, fluoroquinolones (antibiotics), Digoxin (for the treatment of heart failure), Lithium (Control of emotional changes and depression), Sodium polystyrene sulfonate (allows potassium to be removed from the body), Cellulose sodium phosphate (used to prevent kidney stones), Other medicines containing magnesium (including magnesium enemas), Barbiturates (drugs used for the treatment of insomnia), opioids (substances that act as morphine in the body), hypnotics (soporific), Nifedipine (drugs used in high blood pressure or heart problems).
Pregnancy & lactationView
The recommended daily dose in pregnancy and lactation is 1-2 tablets. (During pregnancy & lactation, this product should be used only when clearly needed).
Overdose effectsView
Symptoms of overdose may include slow heartbeat, severe dizziness, confusion, muscle weakness, loss of consciousness, diarrhea and hypermagnesemia.
StorageView
Store below 25°C. Protected from light and moisture. Keep all medicines out of the reach of children.
Magsum
Magnesium Sulfate
Magsum
Magnesium Sulfate
Indications
Hypomagnesemia
Indication detailsView
Magnesium sulfate injection is indicated mainly for the treatment of acute hypomagnesemia and magnesium deficiency states. Magnesium sulfate also has anticonvulsant properties. It can be used for the prevention and control of seizures in pre-eclampsia and eclampsia, respectively.
Therapeutic classView
Specific mineral preparations
PharmacologyView
Magnesium is an important cofactor for enzymatic reactions. It plays an important role in neurochemical transmission and muscular excitability. Magnesium deficiency is accompanied by a variety of different structural and functional disturbances
DosageView
Intramuscular: Adults and older children: For severe hypomagnesemia, 1 to 5 gm (2 to 10 ml of 50% solution) daily in divided doses; administration is repeated daily until serum levels have returned to normal. If deficiency is not severe, 1 gm (2 ml of 50% solution) can be given once or twice daily. Serum magnesium levels should serve as a guide to continued dosage.
Intravenous: 1 to 4 gm magnesium sulfate (magnesium sulfate (magnesium sulfate injection) injection) may be given intravenously in 10% to 20% solution, but only with great caution; the rate should not exceed 1.5 ml of 10% solution or equivalent per minute until relaxation is obtained.
Usual Dose Range: 1 to 40 gm daily.
Electrolyte Replenisher: Intramuscular 1 to 2 gm in 50% solution four times a day until serum magnesium is within normal limits.
Usual Pediatric Dose: Intramuscular 20 to 40 mg per kg of body weight in a 20% solution repeated as necessary.
For Eclampsia: Initially 1 to 2 gm in 25% or 50% solution is given intramuscularly. Subsequently, 1 gm is given every 30 minutes until relief is obtained. The blood pressure should be monitored after each injection.
Intravenous: 1 to 4 gm magnesium sulfate (magnesium sulfate (magnesium sulfate injection) injection) may be given intravenously in 10% to 20% solution, but only with great caution; the rate should not exceed 1.5 ml of 10% solution or equivalent per minute until relaxation is obtained.
Usual Dose Range: 1 to 40 gm daily.
Electrolyte Replenisher: Intramuscular 1 to 2 gm in 50% solution four times a day until serum magnesium is within normal limits.
Usual Pediatric Dose: Intramuscular 20 to 40 mg per kg of body weight in a 20% solution repeated as necessary.
For Eclampsia: Initially 1 to 2 gm in 25% or 50% solution is given intramuscularly. Subsequently, 1 gm is given every 30 minutes until relief is obtained. The blood pressure should be monitored after each injection.
Side effectsView
The most common side effect is hypermagnesaemia developing from excessive administration of magnesium. Symptoms of hypermagnesaemia may include nausea, vomiting, flushing of skin, thirst, hypotension due to peripheral vasodilatation, drowsiness, confusion, muscle weakness etc. Rarely diarrhea or skin irritation after soaking may occur.
ContraindicationsView
Magnesium Sulfate contra-indicated in the case of defect of the heart's electrical message pathways resulting in decreased function of the heart (heart block), severe damage to the muscular wall of the heart (myocardium) and significantly decreased kidney function.
PrecautionsView
Magnesium salts should be administered with caution to patients with impaired renal function or those receiving digitalis glycosides. Parenteral administration of magnesium salts may enhance the effect of neuromuscular blocking agents or of central nervous system depressants. Monitor blood pressure, respiratory rate, urinary output and for signs of over dosage like loss of patellar reflex, weakness, nausea, sensation of warmth, flushing of skin, drowsiness, double vision and slurred speech.
InteractionsView
The dosage of barbiturates, narcotics or other hypnotics (or systemic anesthetics), or other CNS depressants should be adjusted with caution when given in conjunction with magnesium due to the additive depressant effects of magnesium. There may be an increase in the effects of neuromuscular blocking agent when given together with magnesium sulfate. Magnesium sulfate may cause a reduction in blood pressure when administered together with calcium channel blockers.
Pregnancy & lactationView
Pregnancy: Magnesium sulfate injection should be used during pregnancy only if clearly needed. Magnesium sulfate is not known to be harmful for short-term intravenous administration in eclampsia but excessive doses cause neonatal respiratory depression. It is not known whether the drug is excreted in human milk. As it happens with many other drugs, cautions should be taken when it is administered to a nursing mother.
Overdose effectsView
Symptoms of magnesium intoxication are a sharp drop in blood pressure and respiratory paralysis. In the event of overdose, artificial ventilation must be provided until a calcium salt can be injected IV to antagonize the effects of magnesium.
StorageView
Store in a cool & dry place, keep away from light & children.
Majoon Mugalliz
Almond + Coconut + Edible Pine + Salep
Majoon Mugalliz
Almond + Coconut + Edible Pine + Salep
Indications
Nocturnal enuresis
Indication detailsView
This is indicated in
- Spermatorrhoea
- Oligospermia
- Sexual debility
- Nocturnal emission
Therapeutic classView
Herbal and Nutraceuticals
PharmacologyView
This is a unique formulation of Almond (Prunus amygdalus), Coconut (Cocos nucifera), Edible Pine (Pinus gerardiana), Salep (Orchis latifolia), Mastic tree (Pistacia lentiscus), which enhances retentive power and relieves oligospermia. It also prevents sparmatorrhoea and premature ejaculation. This preparation enhances viscosity of semen & prolongs the duration of coitus and ensures post coitus freshness.
DosageView
1-2 teaspoonful(s) twice daily with or as prescribed by the physician.
Side effectsView
No significant side effect has been observed in the therapeutic dosage.
ContraindicationsView
There is no known contraindication.
PrecautionsView
Keep out of reach of the children.
StorageView
Store at cool and dry place, protect from light.
Majoon ard khurma
Acacia + Dates + Asparagus + Edible Pine
Majoon ard khurma
Acacia + Dates + Asparagus + Edible Pine
Indications
Gonorrhoea
Indication detailsView
This is indicated in-
- Sexual debility
- Spermatorrhoea
- Oligospermia
- Gonorrhoea
Therapeutic classView
Herbal and Nutraceuticals
PharmacologyView
This is a unique formulation of Acacia (Acacia arabica), Dates (Phoenix dactylifera), Asparagus (Asparagus racemosus), Edible Pine (Pinus gerardiana), Hazel nut (Corylus avellana), Levant cotton (Gossypium herbaceum), Clove (Eugenia caryophyllus), Nutmeg (Myristica fragrans) etc. It helps to relives sparmatorrhoea, oligospermia and sexual debility. It is an ideal aphrodisiac and nervine tonic.
DosageView
1 teaspoonful twice daily before meal for 2-3 months or as prescribed by the physician.
Side effectsView
No significant side effect has been observed in the therapeutic dosage.
ContraindicationsView
There is no known contraindication.
PrecautionsView
Keep out of reach of the children.
StorageView
Store at cool and dry place, protect from light.
Makcin
Erythromycin (Oral)
Makcin
Erythromycin (Oral)
Indications
Susceptible infections
Indication detailsView
Erythromycin is highly effective in the treatment of a wide variety of clinical infections.
- Upper respiratory tract infections: Tonsilitis, Peritonsillar abscess, Pharyngitis, laryngitis, Sinusitis. Secondary infections in colds and influenza.
- Lower respiratory tract infections: Tracheitis, acute and chronic bronchitis.
- Ear infections: Otitis media, otitis externa, mastoiditis.
- Eye infections: Blepharitis, established trachoma.
- Skin and Soft tissue infections: Boils and carbuncles, impetigo, abscesses, pustular acne, paromychia, cellulitis, erysipelas.
- Gastrointestinal tract infections: Cholecystitis, staphylococcal enterocolitis.
- Prophylaxis: Pre and post-operative, trauma, burns, rheumatic fever.
- Other infections: Osteomyelitis, diptheria, scarlet fever, whooping cough.
Therapeutic classView
Anti-diarrhoeal Antimicrobial drugs, Macrolides
PharmacologyView
Erythromycin inhibits microsomal protein synthesis in susceptible organisms by inhibiting the translocation process. Specific binding to the 50S subunit or 70S ribosome occurs in these organisms but there is no binding to the stable 80S mammalian ribosome. Erythromycin is active against many Grampositive bacteria, some Gram-negative bacteria and against mycoplasmas and chlamydia.
Absorption: Erythromycin base is destroyed by acid and is therefore administered in the form of stable ester. The rates of absorption of the base and esters are diminished by the presence of food. The stearate is hydrolyzed in the intestine and the free erythromycin absorbed.
Blood concentration: After an oral dose of 500 mg. of the base of stearate, peak serum concentrations of 0.9 to 1.4 or 0.4 to 1.8 mg/ml. respectively are attained in 1 to 4 hours. Half-life: The serum half-life is 1.2 to 4 hours. In subjects with oliguria, the half-life is about 5 hours.
Distribution: Erythromycin is widely distributed throughout body tissue and fluids with some retention in the liver and spleen, protein binding of erythromycin base is 73%. Erythromycin enters the cerebrospinal fluid when the meninges are inflamed. It also crosses the placenta and is excreted in the milk.
Excretion: 5 to 15 % of the dose of erythromycin is excreted in the urine and large amounts of the unchanged active substance are excreted in the bile.
Absorption: Erythromycin base is destroyed by acid and is therefore administered in the form of stable ester. The rates of absorption of the base and esters are diminished by the presence of food. The stearate is hydrolyzed in the intestine and the free erythromycin absorbed.
Blood concentration: After an oral dose of 500 mg. of the base of stearate, peak serum concentrations of 0.9 to 1.4 or 0.4 to 1.8 mg/ml. respectively are attained in 1 to 4 hours. Half-life: The serum half-life is 1.2 to 4 hours. In subjects with oliguria, the half-life is about 5 hours.
Distribution: Erythromycin is widely distributed throughout body tissue and fluids with some retention in the liver and spleen, protein binding of erythromycin base is 73%. Erythromycin enters the cerebrospinal fluid when the meninges are inflamed. It also crosses the placenta and is excreted in the milk.
Excretion: 5 to 15 % of the dose of erythromycin is excreted in the urine and large amounts of the unchanged active substance are excreted in the bile.
DosageView
Adult and Children over 8 years: 250-500 mg every six hours for mild to moderate infections. This may be increased upto 4 gm. or more daily in severe cases.
Elderly: No special dosage recommendation. Erythromycin may be administered if desired, three times daily or twice daily by giving one-third or half of the total daily requirement 8 hourly or 12 hourly respectively.
Children aged 2 to 8 years: 250 mg. every six hours or 30-50 mg/kg body weight per day divided into four equal dosage.
Infants and Children upto 2 years: 500 mg. in divided doses or 30-50 mg/kg body weight in divided doses.
Elderly: No special dosage recommendation. Erythromycin may be administered if desired, three times daily or twice daily by giving one-third or half of the total daily requirement 8 hourly or 12 hourly respectively.
Children aged 2 to 8 years: 250 mg. every six hours or 30-50 mg/kg body weight per day divided into four equal dosage.
Infants and Children upto 2 years: 500 mg. in divided doses or 30-50 mg/kg body weight in divided doses.
Side effectsView
Allergic reactions are rare and mild although anaphylaxis has occurred. Occasionally there is abdominal discomfort after oral administration, sometimes with nausea and vomiting. This discomfort usually subsides after a few days without it being necessary to reduce the dosage.
ContraindicationsView
Known hypersensitivity to Erythromycin.
PrecautionsView
Erythromycin should be given with care in patients with impaired hepatic function, as erythromycin is excreted principally in the bile.
InteractionsView
Recent data from studies of erythromycin reveals that its use in patients who are receiving high dosage of theophylline may be associated with an increase of serum theophylline levels and potential theophylline toxicity. In such cases this dose of theophylline should be reduced.
Pregnancy & lactationView
Clinical and Laboratory studies have been shown no evidence in human of teratogenicity or toxicity. However, caution should be exercised when prescribing this drug to pregnant patients and lactating mothers since erythromycin crosses the placental barrier and is excreted in breast milk.
Overdose effectsView
In case of overdosage, Erythromycin should be discontinued. Overdosage should be handled with the prompt elimination of unabsorbed drug and all other appropriate measures should be instituted. Erythromycin is not removed by peritoneal dialysis or haemodialysis.
ReconstitutionView
Direction for reconstitution of suspension: Shake the bottle to loosen powder. Add 60 ml or 100 ml of boiled and cooled water to the dry powder of the bottle. For ease of preparation, add water to the bottle in two proportions. Shake well after each addition until all the powder is in suspension.
Shake the suspension well before each use. Keep the bottle tightly closed. The reconstituted suspension should be stored in a cool and dry place, preferably in refrigerator and unused portion should be discarded after 7 days.
Shake the suspension well before each use. Keep the bottle tightly closed. The reconstituted suspension should be stored in a cool and dry place, preferably in refrigerator and unused portion should be discarded after 7 days.
StorageView
Keep below 25°C temperature, away from light & moisture. Keep out of the reach of children.
Malason
Sulphadoxine + Pyrimethamine
Malason
Sulphadoxine + Pyrimethamine
Indications
Chloroquine-resistant falciparum malaria
Indication detailsView
Treatment of all forms of malaria due to Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae. The drug is also indicated for suppressive or prophylactic management, particularly in areas where resistance to chloroquine is known to exist.
Therapeutic classView
Anti-malarial drugs
PharmacologyView
Sulphadoxine & Pyrimethamine is an antimalarial agent embodying the concept of synergism. Individually the components of this preparation exert inferior result with higher doses in comparison with that obtained with the combination. Moreover, this preparation is effective against strains that are resistant to other antimalarial agents and the risk of resistance development is minimum with this preparation. It is extremely long acting drug, attacks the different development stages of the parasite and attains effective concentration with a single dose. The protective effect of a single dose lasts for approximately four weeks and this preparation is compatible with other antimalarial drugs and with antibiotics. It does not influence the action of antidiabetic agents.
DosageView
Curative treatment of malaria with a single dose-
- Adults: 2-3 tablets
- Children under 4 years: ½ tablets
- 4-8 years: 1 tablet
- 9-14 years: 2 tablets
Suppressive or prophylactic management-
The dose given below should be taken at one time:For semi-immune subjects (Dose: once every four weeks)-
- Adults: 2-3 tablets
- Children under 4 years: ½ tablets
- 4-8 years: 1 tablet
- 9-14 years: 2 tablets
- Adults: 2 tablets
- Children under 4 years: 1½ tablets
- 4-8 years: 1 tablet
- 9-14 years: 1½ tablets
Side effectsView
Sulphadoxine & Pyrimethamine at the recommended dose is well tolerated. Main side effects are given below
- Skin reactions: Drug rash, pruritus and slight hair loss have been observed.
- Gastro-intestinal reactions: Feeling of fullness, nausea, rarely vomiting, stomatitis.
- Haematological reactions: In rare cases, leukopenia, thrombocytopenia, and megaloblastic anemia have been observed.
- Other reactions: Fatigue, headache, fever, polyneuritis may occasionally occur.
ContraindicationsView
Prophylactic (repeated) use of Pyrimethamine + Sulphadoxine is contraindicated in patients with severe renal insufficiency, marked liver parenchymal damage or blood dyscrasias. Treatment must be immediately discontinued upon the appearance of any mucocutaneous signs or symptoms such as pruritus, erythema, rash, orogenital lesions or pharyngitis.
PrecautionsView
Impaired renal or hepatic function, folate deficiency, severe allergy or bronchial asthma, G6PD deficiency, pregnancy. Take with plenty of water to prevent crystalluria. Avoid excessive exposure to sun. Discontinue at the first sign of rash. Discontinue if signs of folic acid deficiency develops. Regular CBC monitoring, LFT, analysis of urine for crystalluria when admin for > 3 mth. Take with food to minimise Gi effects (e.g. anorexia and vomiting).
InteractionsView
Concurrent administration of other preparations containing folate antagonists (e.g. cotrimoxazole, methotrexate, anticonvulsants) can result in increased impairment of folic acid metabolism, which leads to haematological side effects.
Pregnancy & lactationView
Sulphadoxine & Pyrimethamine is contraindicated during pregnancy, premature and newborn infants during the first weeks of life and intolerance to sulfonamide. If pregnancy can not be excluded, possible risks should be balanced against therapeutic effect. Both Pyrimethamine and Sulphadoxine are excreted in maternal breast milk. Nursing mother should not take this preparation.
StorageView
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.